The emergence of dual-action receptor agonists in the treatment of type 2 diabetes and obesity has sparked considerable focus, particularly regarding retatrutide and tirzepatide. While both medications target both the https://jasonubhc167510.pages10.com/retatrutide-vs-tirzepatide-a-comparative-analysis-74162207